Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2009

View Archived Issues

Threitol ceramide, an agonist of invariant NKT cells, may be used as vaccine adjuvant

New triptorelin 6-month formulation safe and efficacious in prostate cancer patients

Novel histone deacetylase inhibitors presented by ArQule

Combining PARP and DNA topoisomerase I inhibitor causes increased toxicity in cancer patients

PSA failures less common with degarelix than with leuprolide in phase III trial

Pfizer provides pipeline update in high-priority disease areas

BTG presents update on clinical development activities for year ended March 2009

Recent GSK patents describe novel Akt inhibitors for cancer treatment

Roche describes novel TAAR1 ligands and their use as antidepressants

New compounds for the treatment of diabetes reported by Boehringer Ingelheim

Potassium channel modulators in early development at Valeant for the treatment of epilepsy

Novel beta-secretase inhibitor shows activity in mouse model of Alzheimer's disease

FDA Advisory Committee discusses liraglutide for the treatment of type 2 diabetes

Pharmos provides update on phase II dextofisopam trial

Traversa Therapeutics' Series B financing to fund RNAi oncology programs

NIH grant to fund study of Cerashield coating in orthopedic implants

OXI-4503 begins phase Ib/IIa study in solid tumors with hepatic involvement

PPD expands its compound partnering program into dermatology

NDA for Zegerid tablet accepted for filing

KS-C370G shows cardioprotective activity in rat model of type 1 diabetes

Japanese launch for Recalbon/Bonoteo Tablets

Patient achieves insulin independence with Diabecell in phase I/IIa trial

AstraZeneca receives FDA complete response on Symbicort for pediatric asthma

Capstone initiates dosing in phase II AZX-100 pilot study in keloid scarring

Eisai enters into agreement with Nobelpharma for Gliadel Wafer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...